Azitra, Inc.
AZTRNext catalyst
ATR04-484
EGFR Inhibitor-associated Rash
Get an email about AZTR's next catalysts
Track Azitra (AZTR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
AZTR Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.20 | FQ end Sep/2026 | Call: tbd
ATR04-484 Phase 2 Est. Readout
Primary completion for ATR04-484 trial (NCT06830863) in EGFR Inhibitor-associated Rash
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ATR04-484 | Phase 2 | EGFR Inhibitor-associated Rash | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Azitra, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Azitra, Inc.'s (AZTR) pipeline across Phase 2. Its lead program is ATR04-484 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Azitra, Inc.'s next FDA catalyst?→
Azitra, Inc.'s (AZTR) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AZTR biotech catalysts?→
Add AZTR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Azitra, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.